Lilly(Eli) & Co
LLY
Get informed when a big investor buys or sells
+ FollowEarnings Call Q1 2026
April 30, 2026 - AI Summary
Exclusive for Stockcircle Pro members
Sign up
Current Fair Value
40.3% downsideOvervalued by 40.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.03 Trillion |
|---|---|
| Enterprise Value | $1.08 Trillion |
| Dividend Yield | $6.46 (0.59%) |
| Earnings per Share | $23 |
| Beta | 0.52 |
| Outstanding Shares | 894,500,000 |
Return
| Return on Equity | 81.01% |
|---|---|
| Return on Assets | 21.68% |
| Return on Invested Capital | 39.21% |
Valuation & Multiples
| P/E Ratio | 38.86 |
|---|---|
| PEG | 23.13 |
| Price to Sales | 13.8 |
| Price to Book Ratio | 32.46 |
| Enterprise Value to Revenue | 14.91 |
| Enterprise Value to EBIT | 34.38 |
| Enterprise Value to Net Income | 42 |
| Total Debt to Enterprise | 0.05 |
| Debt to Equity | 1.56 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Next Earnings Call
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.4968▲ 47.77% |
|---|---|
| Total Calls | 8,355,932▼ 34.41% |
| Total Puts | 12,507,501▼ 3.66% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 86.41%▼ 1.68% |
|---|---|
| Total Invested | $712.54B▼ 15.48% |
| Investors Holding | 4,478▼ 82.00% |
ESG Score
No data
About Lilly(Eli) & Co
CEO: David Ricks Relevant Senate Committees
This committee provides the official revenue estimates and technical analysis for all tax legislation. Its reports and expertise directly influence corporate tax structures, capital investment credits, and the overall tax burden on industries like pharmaceuticals, profoundly affecting Eli Lilly's profitability and financial strategy.
This is a powerful committee that controls taxation, trade, and entitlement spending. It directly impacts Eli Lilly through corporate tax policy, trade regulations affecting global supply chains, and, critically, through its influence on Medicare/Medicaid drug pricing, which is a major revenue driver for pharmaceutical companies.
This committee allocates discretionary federal spending. Its subcommittees determine precise funding for the FDA, NIH, and major healthcare programs (like Medicare/Medicaid). These funding decisions directly impact the regulatory environment, research landscape, and drug purchasing power relevant to Eli Lilly.
This committee has direct oversight of the FDA, which is the primary regulatory body for drug approval, manufacturing, and marketing for Eli Lilly. It also influences NIH funding, which supports foundational research relevant to drug discovery, and labor laws impacting LLY's workforce.
This committee oversees intellectual property laws (crucial for pharmaceutical patents) and antitrust regulations. Patent protection is fundamental to Eli Lilly's business model, and antitrust decisions can impact mergers, acquisitions, and market competition within the industry.
While advisory, this committee's investigations into drug pricing and healthcare for older Americans create significant 'headline risk' and public/political pressure. Given the current scrutiny on pharmaceutical pricing, this directly impacts the environment in which Eli Lilly operates and potential future legislative action.
This committee oversees the Department of Veterans Affairs, which is a significant purchaser of pharmaceutical products. Funding decisions made by this committee directly impact the VA healthcare system's budget and, consequently, Eli Lilly's sales to a major government customer.